AdaptHealth (NASDAQ:AHCO) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

AdaptHealth (NASDAQ:AHCO) had its price target raised by Canaccord Genuity Group from $13.00 to $14.00 in a research report report published on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on the company. Truist Financial boosted their price objective on AdaptHealth from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada upped their price target on shares of AdaptHealth from $11.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday. Robert W. Baird decreased their price objective on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, UBS Group lowered their target price on shares of AdaptHealth from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $13.40.

AdaptHealth Stock Performance

NASDAQ:AHCO opened at $11.10 on Wednesday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24. The stock has a 50-day simple moving average of $9.87 and a two-hundred day simple moving average of $10.21. The firm has a market capitalization of $1.49 billion, a PE ratio of -6.73, a P/E/G ratio of 1.08 and a beta of 1.12. AdaptHealth has a 52-week low of $8.35 and a 52-week high of $11.90.

Institutional Investors Weigh In On AdaptHealth

A number of institutional investors have recently added to or reduced their stakes in AHCO. Blue Trust Inc. lifted its holdings in shares of AdaptHealth by 24.1% in the fourth quarter. Blue Trust Inc. now owns 5,746 shares of the company’s stock worth $55,000 after buying an additional 1,115 shares in the last quarter. Guggenheim Capital LLC increased its holdings in AdaptHealth by 10.1% in the 4th quarter. Guggenheim Capital LLC now owns 16,613 shares of the company’s stock valued at $158,000 after acquiring an additional 1,525 shares during the last quarter. Sterling Capital Management LLC lifted its stake in AdaptHealth by 5.2% in the 4th quarter. Sterling Capital Management LLC now owns 33,558 shares of the company’s stock worth $319,000 after purchasing an additional 1,644 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of AdaptHealth by 15.4% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,663 shares of the company’s stock valued at $121,000 after purchasing an additional 1,690 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of AdaptHealth by 0.5% during the fourth quarter. Rhumbline Advisers now owns 313,110 shares of the company’s stock valued at $2,981,000 after purchasing an additional 1,691 shares in the last quarter. 82.67% of the stock is owned by hedge funds and other institutional investors.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.